)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Palatin Technologies
Palatin Technologies (PTN) investor relations material
Palatin Technologies Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary17 Feb, 2026
Executive summary
Advanced melanocortin receptor (MCR) agonist pipeline, focusing on rare neuroendocrine and genetic obesity disorders, with lead MC4R programs targeting hypothalamic obesity and Prader-Willi syndrome and additional MC1R assets for ocular, gastroenterology, and renal indications.
Strengthened financial position through an $18.2 million public offering, regaining NYSE American listing compliance, and significant equity financing and warrant exercises totaling $18.35 million in the six months.
Entered a major research collaboration and license agreement with Boehringer Ingelheim for retinal disease therapeutics, generating upfront and milestone revenue.
Sublicensed PL9643 for dry eye disease, securing $3.8 million in upfront non-cash debt cancellation and eligibility for future milestones and royalties.
Financial highlights
Collaboration and license revenue rose to $8.96 million for the six months ended December 31, 2025, mainly from the Boehringer Ingelheim agreement; Q2 FY26 revenue was $116,036, up from $0 year-over-year.
Operating expenses increased to $7.4 million for the quarter, driven by higher R&D and compensation costs.
Net loss for Q2 FY26 was $7.3 million ($2.86/share), compared to $2.4 million ($5.92/share) in the prior year; net loss for the six months was $2.59 million.
Cash and cash equivalents stood at $14.5 million as of December 31, 2025, with current liabilities of $6.33 million.
Cash runway expected to extend beyond March 31, 2027.
Outlook and guidance
IND submission and Phase 1 trial for oral MC4R agonist PL7737 planned for H1 2026; next-generation peptide MC4R agonist IND submission targeted for H2 2026.
Multiple clinical trials for rare MC4R pathway diseases are planned for calendar year 2026.
Phase II/III studies in hypothalamic obesity and Prader-Willi syndrome to begin after mid-2027.
Sufficient cash on hand to fund phase 1 studies for both oral and peptide programs.
Additional funding will be required to complete clinical trials and regulatory submissions.
When do you anticipate Series J warrants to be exercised?
How will PL-7737 GI tolerability be confirmed?
GLP-1 combination: impact on future studies?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Palatin Technologies earnings date
Q3 202613 May, 2026
Palatin Technologies
Next Palatin Technologies earnings date
Q3 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The Company's lead product candidate is bremelanotide, which is under review by the U.S. Food and Drug Administration (FDA) for the potential treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women; and the treatment of benign prostatic hyperplasia (BPH) in men. The Company has its U.S.-based headquarters and research facility located in Cranbury, New Jersey.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage